No price history available.
Key financial summary
Financials in JPY| 2020 | 2021 | 2022 | 2023 | 2024 | 2025 | TTM | 2026E | ||
|---|---|---|---|---|---|---|---|---|---|
| Total revenue | ¥m | 28,618 | 28,835 | 30,594 | 32,397 | 33,232 | 33,942 | N/A | N/A |
| Operating profit | ¥m | Locked | Locked | Locked | Locked | Locked | Locked | Locked | Locked |
| Net profit | ¥m | 1,130 | 1,154 | -316 | 1,964 | 1,092 | 1,135 | N/A | N/A |
| EPS reported | ¥ | Locked | Locked | Locked | Locked | Locked | Locked | Locked | Locked |
| Operating cashflow per share | ¥ | Locked | Locked | Locked | Locked | Locked | Locked | Locked | Locked |
| Capex per share | ¥ | Locked | Locked | Locked | Locked | Locked | Locked | Locked | Locked |
| FCF per share | ¥ | Locked | Locked | Locked | Locked | Locked | Locked | Locked | Locked |
| Free cash flow | ¥m | Locked | Locked | Locked | Locked | Locked | Locked | Locked | Locked |
| Net debt | ¥m | Locked | Locked | Locked | Locked | Locked | Locked | Locked | Locked |
| Book value equity | ¥m | Locked | Locked | Locked | Locked | Locked | Locked | Locked | Locked |
| Book value per share | ¥ | Locked | Locked | Locked | Locked | Locked | Locked | Locked | Locked |
| Number of shares | m | Locked | Locked | Locked | Locked | Locked | Locked | Locked | Locked |
| DPS (TTM paid) | ¥ | Locked | Locked | Locked | Locked | Locked | Locked | Locked | Locked |
Financial summary
Financials in JPY| 2020 | 2021 | 2022 | 2023 | 2024 | 2025 | TTM | 2026E | ||
|---|---|---|---|---|---|---|---|---|---|
| Value | |||||||||
| P/E LTM | x | Locked | Locked | Locked | Locked | Locked | Locked | Locked | Locked |
| P/B LTM | x | Locked | Locked | Locked | Locked | Locked | Locked | Locked | Locked |
| P/S LTM | x | Locked | Locked | Locked | Locked | Locked | Locked | Locked | Locked |
| P/FCF LTM | x | Locked | Locked | Locked | Locked | Locked | Locked | Locked | Locked |
| EV/EBITDA LTM | x | Locked | Locked | Locked | Locked | Locked | Locked | Locked | Locked |
| EV/Sales LTM | x | Locked | Locked | Locked | Locked | Locked | Locked | Locked | Locked |
| Earnings Yield LTM | % | Locked | Locked | Locked | Locked | Locked | Locked | Locked | Locked |
| FCF Yield | % | Locked | Locked | Locked | Locked | Locked | Locked | Locked | Locked |
| Quality | |||||||||
| ROE | % | Locked | Locked | Locked | Locked | Locked | Locked | Locked | Locked |
| ROIC | % | Locked | Locked | Locked | Locked | Locked | Locked | Locked | Locked |
| Operating margin | % | Locked | Locked | Locked | Locked | Locked | Locked | Locked | Locked |
| Gross margin | % | Locked | Locked | Locked | Locked | Locked | Locked | Locked | Locked |
| FCF/Sales | % | Locked | Locked | Locked | Locked | Locked | Locked | Locked | Locked |
| Growth and momentum | |||||||||
| EPS Growth YoY | % | Locked | Locked | Locked | Locked | Locked | Locked | Locked | Locked |
| Sales Growth YoY | % | Locked | Locked | Locked | Locked | Locked | Locked | Locked | Locked |
| Net Income Growth YoY | % | Locked | Locked | Locked | Locked | Locked | Locked | Locked | Locked |
| FCF Growth | % | Locked | Locked | Locked | Locked | Locked | Locked | Locked | Locked |
| Operating Profit Growth | % | Locked | Locked | Locked | Locked | Locked | Locked | Locked | Locked |
| Dividend and capital structure | |||||||||
| Dividend Yield | % | Locked | Locked | Locked | Locked | Locked | Locked | Locked | Locked |
| Dividend Growth | % | Locked | Locked | Locked | Locked | Locked | Locked | Locked | Locked |
| Payout Ratio | % | Locked | Locked | Locked | Locked | Locked | Locked | Locked | Locked |
| FCF/Debt | x | Locked | Locked | Locked | Locked | Locked | Locked | Locked | Locked |
| Net Debt/EBITDA | x | Locked | Locked | Locked | Locked | Locked | Locked | Locked | Locked |
| EBIT/Net interest | x | Locked | Locked | Locked | Locked | Locked | Locked | Locked | Locked |
| Net debt/market cap | % | Locked | Locked | Locked | Locked | Locked | Locked | Locked | Locked |
| Net debt/Equity | % | Locked | Locked | Locked | Locked | Locked | Locked | Locked | Locked |
| Gross debt/equity | % | Locked | Locked | Locked | Locked | Locked | Locked | Locked | Locked |
Ratings
Based on consensus from external analysts. Not Kvantra's opinion.
Company overview
SEED Co.,Ltd. is an international manufacturer and supplier specializing in a broad spectrum of ophthalmic products. The company's extensive range includes various contact lenses, lens care solutions, fashionable spectacle frames, and other vision enhancement items, serving customers in Japan and across global markets. Their diverse contact lens collection features numerous daily disposable options, such as the SEED 1dayPure moisture, SEED Eye coffret 1day UV, SEED 1dayPure EDOF, SEED PlusMode 1day Homme, and JILL STUART 1day UV. They also offer specialized daily lenses, including multistage and astigmatism-correcting versions like the SEED 1dayPure moisture for astigmatism. Furthermore, SEED provides two-week disposable lenses through its SEED 2weekPure moisture series, which encompasses standard, multistage bifocal, and astigmatism-specific variants. Monthly replacement lenses, such as SEED MonthlyFine UV and monthly color lens UV, are also part of their portfolio, alongside advanced rigid gas permeable and medical contact lenses. In addition to vision correction products, SEED Co.,Ltd. designs and sells eyewear frames under well-known brands like Vivid Moon, ViVi fleurs, and Plusmix. The company also develops pharmaceutical products, including Adeno Test AD for the detection of adenovirus antigens, and other solutions aimed at improving visual health. Established in 1957, SEED Co.,Ltd. is based in Tokyo, Japan.
Similar companies
For informational purposes only. Kvantra provides data and quantitative analysis, not investment advice. KvantraRank is a mechanical model output. Analyst price targets and ratings are sourced from third parties and are not Kvantra recommendations. Past performance does not guarantee future results; all investments carry risk.
No price history available.
Not enough data to calculate KvantraRank
Based on consensus from external analysts. Not Kvantra's opinion.
SEED Co.,Ltd. is an international manufacturer and supplier specializing in a broad spectrum of ophthalmic products. The company's extensive range includes various contact lenses, lens care solutions, fashionable spectacle frames, and other vision enhancement items, serving customers in Japan and across global markets. Their diverse contact lens collection features numerous daily disposable options, such as the SEED 1dayPure moisture, SEED Eye coffret 1day UV, SEED 1dayPure EDOF, SEED PlusMode 1day Homme, and JILL STUART 1day UV. They also offer specialized daily lenses, including multistage and astigmatism-correcting versions like the SEED 1dayPure moisture for astigmatism. Furthermore, SEED provides two-week disposable lenses through its SEED 2weekPure moisture series, which encompasses standard, multistage bifocal, and astigmatism-specific variants. Monthly replacement lenses, such as SEED MonthlyFine UV and monthly color lens UV, are also part of their portfolio, alongside advanced rigid gas permeable and medical contact lenses. In addition to vision correction products, SEED Co.,Ltd. designs and sells eyewear frames under well-known brands like Vivid Moon, ViVi fleurs, and Plusmix. The company also develops pharmaceutical products, including Adeno Test AD for the detection of adenovirus antigens, and other solutions aimed at improving visual health. Established in 1957, SEED Co.,Ltd. is based in Tokyo, Japan.